Will new statin guidelines lead to overtreatment?

References

• National Cholesterol Education Program Expert Panel. Report on detection, evaluation, and treatment of high blood cholesterol in adults. Arch. Intern. Med. 148, 36–69 (1988).
   Google Scholar
• Smith GD, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ 304(6824), 431–434 (1992).
   Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285(19), 2486–2497 (2001).
   Google Scholar
• Ebrahim S, Casas JP. Statins for all by the age of 50 years? Lancet 380(9841), 545–547 (2012).
   Google Scholar
• Herper M. As statins soar, use of other cholesterol medicines declines. Forbes (2013). www.forbes.com/sites/matthewherper/2013/05/29/as-statins-soar-use-of-other-cholesterol-medicines-declines/
   Google Scholar
• King S. The best selling drugs of all time; Humira joins the elite. Forbes (2013). www.forbes.com/sites/simonking/2013/01/28/the-bestselling-drugs-of-all-time-humira-joins-the-elite
   Google Scholar
• Associated Press. It took a brilliant marketing campaign to create the best-selling drug of all time. Business Insider, 28th December (2011).
   Google Scholar
• Stone NJ, Robinson J, Lichtenstein AH et al. 2013 ACC/ AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. doi:10.1016/j.jacc.2013.11.002 (2013) (Epub ahead of print).
   Google Scholar
• Krumholz HM. Target cardiovascular risk rather than cholesterol concentration. BMJ 347, f7110 (2013).
   Google Scholar
• Khanna R. 7.5% – what a curious number. JAMA International Medicine Blog, 27th November (2013).
   Google Scholar
• Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet 382, 1762–1765 (2013).
   Google Scholar
• Downs J, Good C. New cholesterol guidelines: has Godot finally arrived? Ann. Intern. Med. doi:10.7326/M13-2850 (2014) (Epub ahead of print).
   Google Scholar
• Parker-Pope T. 8 year-olds on statins? A new plan quickly bites back. New York Times, 8th July (2008).
   Google Scholar
• Ridker PM, Danielson E, Fonseca FA et al.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359(21), 2195–2207 (2008).
   Google Scholar
• Kaul S, Morrissey RP, Diamond GA. By Jove! What is a clinician to make of JUPITER? Arch. Intern. Med. 170(12), 1073–1077 (2010).
   Google Scholar
• de Lorgeril M, Salen P, Abramson J et al. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin – JUPITER controversy: a critical reappraisal. Arch. Intern. Med. 170(12), 1032–1036 (2010).
   Google Scholar
• Brugts JJ, Yetgin T, Hoeks SE et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 338, b2376 (2009).
   Google Scholar
• Tonelli M, Lloyd A, Clement F et al.; Alberta Kidney Disease Network. Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. CMAJ 183(16), E1189–E1202 (2011).
   Google Scholar
• Taylor F, Huffman MD, Macedo AF et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst. Rev. 1, CD004816 (2013).
   Google Scholar
• Thavendiranathan P, Bagai A, Brookhart MA et al. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomizedcontrolled trials. Arch. Intern. Med. 166(21), 2307–2303 (2006).
   Google Scholar
• Ray KK, Seshasai SR, Erqou S et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch. Intern. Med. 170(12), 1024–1031 (2010).
   Google Scholar
• Therapeutics Initiative. Do statins have a role in primary prevention? An update. Therapeutics Letter 77, 1–2 (2010).
   Google Scholar
• Mihaylova B, Emberson J, Blackwell L et al.; Cholesterol Treatment Trialists’ (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380(9841), 581–590 (2012).
   Google Scholar
• Abramson JD, Rosenberg HG, Jewell N, Wright JM. Should people at low risk of cardiovascular disease take a statin? BMJ 347, f6123 (2013).
   Google Scholar
• The Lancet. Supplementary Appendix. Supplement to: Cholesterol Treatment Trialists’ (CTT) Collaborators. The effects oflowering LDL cholesterol with statin therapy in people at low risk of vascular disease:meta-analysis of individual data from 27 randomised trials. Lancet published online May 17. doi:10.1016/S0140-6736(12)60367-5 (2012). http://download.thelancet.com/mmcs/journals/lancet/PIIS0140673612603675/mmc1.pdf?id=baaMfg8arLLkAezldaauu
   Google Scholar
• Newman D. Statin drugs given for 5 years for heart disease prevention (without known heart disease). www.thennt.com/nnt/statins-for-heart-disease-preventionwithout-prior-heart-disease
   Google Scholar
• Weymiller AJ, Montori VM, Jones LA et al. Helping patients with Type 2 diabetes mellitus make treatment decisions: statin choice randomized trial. Arch. Intern. Med. 167(10), 1076–1082 (2007).
   Google Scholar
• Fernandez G, Spatz ES, Jablecki C et al. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve. Clin. J. Med. 78(6), 393–403 (2011).
   Google Scholar
• Carling CL, Kristoffersen DT, Montori VM et al. The effect of alternative summary statistics for communicating risk reduction on decisions about taking statins: a randomized trial. PLoS Med. 6(8), e1000134 (2009).
   Google Scholar
• Leape LL, Weissman JS, Schneider EC et al. Adherence to practice guidelines: the role of specialty society guidelines. Am. Heart J. 145(1), 19–26 (2003).
   Google Scholar
• Ardery G, Carter BL, Milchak JL et al. Explicit and implicit evaluation of physician adherence to hypertension guidelines. J. Clin. Hypertens. 9(2), 113–119 (2007).
   Google Scholar
• McKinlay JB, Link CL, Freund KM et al. Sources of variation in physician adherence with clinical guidelines: results from a factorial experiment. J. Gen. Intern. Med. 22(3), 289–296 (2007).
   Google Scholar
• Shaneyfelt TM, Mayo-Smith MF, Rothwangl J. Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. JAMA 281(20), 1900–1905 (1999).
   Google Scholar
• Lenzer J, Hoffman JR, Furberg CD et al.; Guideline Panel Review Working Group. Ensuring the integrity of clinical practice guidelines: a tool for protecting patients. BMJ 347, f5535 (2013).
   Google Scholar
• Shackelton RJ, Marceau LD, Link CL, McKinlay JB. The intended and unintended consequences of clinical guidelines. J. Eval. Clin. Pract. 15(6), 1035–1042 (2009).
   Google Scholar
• Dachs R, Darby-Stewart A, Graber MA. How do clinical practice guidelines go awry? Am. Fam. Physician 86(6), 514–516 (2012).
   Google Scholar
• Ransohoff DF, Pignone M, Sox HC. How to decide whether a clinical practice guideline is trustworthy. JAMA 309(2), 139–140 (2013).
   Google Scholar
• Grol R, Dalhuijsen J, Thomas S et al. Attributes of clinical guidelines that influence use of guidelines in general practice: observational study. BMJ 317(7162), 858–861 (1998).
   Google Scholar